<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949819</url>
  </required_header>
  <id_info>
    <org_study_id>11-002281</org_study_id>
    <nct_id>NCT00949819</nct_id>
  </id_info>
  <brief_title>Active Surveillance for Cancer of the Prostate (ASCaP)</brief_title>
  <acronym>ASCaP</acronym>
  <official_title>The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with&#xD;
      low-risk, localized lesions, with curative treatment of those whose tumors show substantial&#xD;
      progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative&#xD;
      treatment of men with progressive prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is not designed as a formal clinical trial, but rather an observational&#xD;
      protocol; no treatments and no randomization are included. Longitudinally, specimens and&#xD;
      clinical data will be collected to provide information on the following:&#xD;
&#xD;
        -  Imaging studies of the prostate&#xD;
&#xD;
        -  Rates of curative intervention&#xD;
&#xD;
        -  Measures of tumor recurrence/progression&#xD;
&#xD;
        -  Disease specific survival&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
        -  Clinical data to track Quality of Life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2009</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 4, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discover and confirm clinical parameters that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.</measure>
    <time_frame>Interim data analysis will be made every year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the clinical predictors of disease progression. Measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. Determine factors that lead to active intervention</measure>
    <time_frame>Interim data analysis will be done each year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <description>Men with previously untreated, early stage prostate cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active surveillance</intervention_name>
    <description>Serial, long term data collection and active surveillance</description>
    <arm_group_label>no treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, buffy coat, prostate tissue cores and urine.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the prostate.&#xD;
&#xD;
          2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.&#xD;
&#xD;
          3. No previous treatment for prostate cancer (including hormonal therapy, radiation&#xD;
             therapy, surgery, or chemotherapy).&#xD;
&#xD;
          4. Patient has elected Active Surveillance as preferred management plan for prostate&#xD;
             cancer.&#xD;
&#xD;
          5. Patient consent has been obtained according to local Institutional Review Board .&#xD;
&#xD;
          6. Patient is accessible and compliant for follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwillingness or inability to undergo serial prostate biopsy.&#xD;
&#xD;
          2. Overall life expectancy less than 2 years&#xD;
&#xD;
          3. Advanced prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard S Marks, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malu Macairan</last_name>
    <phone>(310) 794-3566</phone>
    <email>mmacairan@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonard S Marks, M.D.</last_name>
    <phone>(310) 794-3070</phone>
    <email>lmarks@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonard S Marks, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Low risk</keyword>
  <keyword>Gleason 6</keyword>
  <keyword>Active surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

